慢性病缓释注射剂市场

Chronic Disease Markets for Sustained Release Injectables - Extended Coverage Version

出版日期: 2023年12月04日 | 出版商:

Greystone Research Associates | 英文 225 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

慢性病需要长期用药，自我用药变得越来越重要。随着护理人员互动的转变，用药安全和依从性/依从性成为突出问题。这些担忧并不新鲜，但随着越来越多强大的新药进入市场，这些担忧也越来越严重。对于医疗保健管理者和公共卫生官员来说，解决这些问题的一种方法是减少给药次数。使用旨在调节治疗物质作用的製剂技术，药物开发商正在开发具有缓释特性的製剂。此类製剂技术包括聚乙二醇缀合物（聚乙二醇化）等聚合物，用于封装和包覆新药物。目标是透过控释製剂满足患者依赖性、依从性敏感的多剂量类药物治疗方案的要求，控释製剂可以每天给药一次或更少，以达到所需的治疗效果。

本报告研究了全球慢性病缓释注射剂市场，并提供了市场现状、注射剂技术趋势、需求驱动因素、竞争格局和未来预测。Masu。

自我管理的趋势
注射配方技术
注射装置设计的创新
推动治疗需求的因素
市场因素
竞争状况
风险因素
持续释放 - 品牌配方技术
可生物降解聚合物
品牌SR混炼技术
物理过程控制方法
缓释注射液 - 开发因素
组成元素
稳定性
冻干
包装
管理因素
SR 注塑 - 产品

市场领域分析与预测

成瘾
纳曲酮
糖尿病
艾塞那□
传染病
干扰素
荷尔蒙缺乏
雌二醇
生长激素
睪酮
代谢性疾病
肢端肥大症
神经病学
肿瘤学
白血病
淋巴瘤
阿糖胞甘
摄护腺
疼痛管理
生殖健康
生育能力
子宫内膜异位症

市场概况

简介目录

Product Code: SRK389F

“Chronic Disease Markets for Sustained Release Injectables: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.